Cancer Tissue Diagnostics Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
The cancer tissue diagnostics market is projected to reach US$ 3,640.87 million by 2028 from US$ 2,538.31 million in 2022; it is estimated to grow at a CAGR of 6.2% from 2022 to 2028.
Cancer tissue diagnostics techniques are used to detect a tumor in malignant tissues. In the last few years, immunohistochemistry (IHC) was used to increase the detection of specific antigens in tumor tissue. With the help of nonfluorescent chromogens, the screening is analyzed with conventional microscopy. There are recent techniques developed for cancer tissue diagnosis. Fluorescence in situ hybridization is used to examine a genetic abnormality in the genome. The hybridized deoxyribonucleic acid (DNA) is examined with particular probes.
The cancer tissue diagnostics market is segmented on the basis of test type and geography. Based on test type, the market is segmented into immunohistochemical tests and in situ hybridization tests. In 2022, the immunohistochemical tests segment held a larger market share. The market in the same segment is also anticipated to grow at a faster rate in the coming years. By geography, the cancer tissue diagnostics market is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The market in Asia Pacific is expected to grow at the highest rate during the forecast period owing to the rising prevalence of cancer and the increasing aging population in Asian countries. The Japanese Government has been formulating and laying down multiple initiatives and programs to enhance the quality of cancer treatment and increase awareness regarding cancer in the country. In China, as per data by the WHO, 45,68,754 new cancer cases were detected, and 30,02,899 cancer deaths were recorded in the country in 2020. The cancer tissue diagnostics report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, market dynamics, and the competitive analysis of the globally leading market players.
Strategic Insights
Market Insights
New Product Launches and FDA Approvals and growing investments in Cancer Tissue Diagnostics to Fuel Cancer Tissue Diagnostics Market During Forecast Period
Most major market players are involved in manufacturing a wide range of cancer diagnostics products offering maximum advantages and early diagnosis. In June 2022, Roche announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.
In March 2022, Illumina launched a new in vitro diagnostic test in Europe designed to profile various cancer mutations and help direct patients to targeted therapies. Thus, the constant technological developments in diagnostics and FDA approvals accelerate the market growth.
Furthermore, tissue diagnostics is crucial in cancer treatment. Cancer tissue diagnostics play a significant role in determining the treatment pace and procedure. Early detection can help reduce the mortality rates of cancer; hence, medical professionals, market players, and government authorities implement new diagnostics and treatment facilities. Thus, the rise in investments and better policies of reimbursement favor the growth of the cancer tissue diagnostics market.
In May 2021, QIAGEN N.V. launched an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN). Furthermore, In January 2020, Illumina and Roche signed a 15-year, non-exclusive collaboration agreement designed to realize NGS’ potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. The value of the partnership—which includes in vitro diagnostic (IVD) and companion diagnostics (CDx) initiatives—was not disclosed. In 2019, the company launched AIforia cloud platform that accelerates image processing and provides automated pathology image analysis. Thus, the increasing collaborations and new technological platforms in cancer tissue diagnostics have led to the advent of breakthrough techniques, which are expected to fuel the growth of the market in the coming years.
Test Type-Insights
Based on test type, the cancer tissue diagnostics market is segmented into immunohistochemical tests and in situ hybridization tests. In 2022, the immunohistochemical tests segment held a larger market share. In addition, the market in the same segment is expected to grow at a faster rate in the coming years owing to the cost-effectiveness of the technique. Moreover, the technique is easily accessible, and growth in the number of products based on technology are further expected to drive the segment growth.
Product launches and collaborations are highly adopted strategies by the global cancer tissue diagnostics market players. A few of the recent key market developments are listed below:
- In June 2022, Roche announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.
- In March 2022, Illumina launched a new in vitro diagnostic test in Europe designed to profile various cancer mutations and help direct patients to targeted therapies.
- In May 2021, QIAGEN N.V. launched an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN).
- In January 2020, Illumina and Roche signed a 15-year, non-exclusive collaboration agreement designed to realize NGS’ potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. The value of the partnership—which includes in vitro diagnostic (IVD) and companion diagnostics (CDx) initiatives—was not disclosed.
- In June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to identify patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck.
- In June 2019, Thermo Fisher Scientific's Oncomine Dx Target Test received reimbursement coverage from Japan's Ministry of Health, Labour and Welfare. The test is now commercially available in Japan. The reimbursement has helped the company to offer the diagnosis of NSCLC.\
- In May 2019, Roche launched the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody, an in vitro diagnostic ROS1 immunohistochemistry (IHC) assay. The launch has enabled the company to offer better innovative products.
Company Profiles
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc
- Bio Rad Laboratories Inc
- Abbott
- Enzo Life Sciences, Inc
- Agilent Technologies, Inc
- Cancer Genetics Inc
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Danaher Corporation
- Abcam plc.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Test Type
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Cancer Tissue Diagnostics Market – By Test Type
1.3.2 Global Cancer Tissue Diagnostics Market – By Geography
2. Global Cancer Tissue Diagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Cancer Tissue Diagnostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East & Africa PEST Analysis
4.2.5 South & Central America PEST Analysis
5. Global Cancer Tissue Diagnostics Market – Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Growing Cancer Prevalence Across The Globe
5.1.2 New Product Launches & FDA Approvals
5.1.3 Growing Investments For Tissue Diagnostics
5.2 Key Market Restraints
5.2.1 High Cost Of Cancer Diagnostics
5.3 Key Market Opportunities
5.3.1 Emerging Markets in Developing Countries
5.4 Future Trends
5.4.1 Inclination Towards Personalized Medicine
5.5 Impact Analysis
6. Cancer Tissue Diagnostics Market – Global Analysis
6.1 Global Cancer Tissue Diagnostics Market Revenue Forecasts And Analysis
6.2 Global Cancer Tissue Diagnostics Market, By Geography - Forecasts And Analysis
6.3 Performance of Key Players
7. Global Cancer Tissue Diagnostics Market Analysis– by Test Type
7.1 Overview
7.2 Global Cancer Tissue Diagnostics Market, By Test Type 2018 & 2027 (%)
7.3 Immunohistochemical Tests Market
7.3.1 Overview
7.3.2 Global Immunohistochemical Tests Market Revenue and Forecasts to 2027 (US$ Mn)
7.3.3 Breast Cancer Market
7.3.3.1 Overview
7.3.3.2 Global Breast Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
7.3.4 Colorectal Cancer Market
7.3.4.1 Overview
7.3.4.2 Global Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
7.3.5 Prostate Cancer Market
7.3.5.1 Overview
7.3.5.2 Global Prostate Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
7.3.6 Stomach Cancer Market
7.3.6.1 Overview
7.3.6.2 Global Stomach Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
7.3.7 Others Market
7.3.7.1 Overview
7.3.7.2 Global Others Market Revenue and Forecasts to 2027 (US$ Mn)
7.4 In Situ Hybridization Tests Market
7.4.1 Overview
7.4.2 Global In Situ Hybridization Tests Market Revenue and Forecasts to 2027 (US$ Mn)
7.4.3 Breast Cancer Market
7.4.3.1 Overview
7.4.3.2 Global Breast Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
7.4.4 Lung Cancer Market
7.4.4.1 Overview
7.4.4.2 Global Lung Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
7.4.5 Bladder Cancer Market
7.4.5.1 Overview
7.4.5.2 Global Bladder Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
7.4.6 Others Market
7.4.6.1 Overview
7.4.6.2 Global Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 – Geographical Analysis
8.1 North America Cancer Tissue Diagnostics Market Revenue And Forecasts To 2027
8.1.1 North America Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.1.2 North America Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.1.2.1 North America Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.1.2.2 North America In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.1.3 North America Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027, By Country (%)
8.1.4 US Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.1.4.1 US Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.1.4.2 US Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.1.4.2.1 US Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.1.4.2.2 US In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.1.5 Canada Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.1.5.1 Canada Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.1.5.2 Canada Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.1.5.2.1 Canada Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.1.5.2.2 Canada In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.1.6 Mexico Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.1.6.1 Mexico Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.1.6.2 Mexico Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.1.6.2.1 Mexico Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.1.6.2.2 Mexico In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2 Europe Cancer Tissue Diagnostics Market Revenue And Forecasts To 2027
8.2.1 Europe Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.2 Europe Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.2.2.1 Europe Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.2.2 Europe In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.3 Europe Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
8.2.4 UK Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.4.1 UK Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.4.2 UK Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.2.4.2.1 UK Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.4.2.2 UK In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.5 Germany Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.5.1 Germany Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.5.2 Germany Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.2.5.2.1 Germany Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.5.2.2 Germany In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.6 France Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.6.1 France Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.6.2 France Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.2.6.2.1 France Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.6.2.2 France In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.7 Italy Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.7.1 Italy Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.7.2 Italy Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.2.7.2.1 Italy Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.7.2.2 Italy In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.8 Spain Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.8.1 Spain Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.2.8.2 Spain Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.2.8.2.1 Spain Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.2.8.2.2 Spain In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3 Asia Pacific Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027
8.3.1 Asia Pacific Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.2 Asia Pacific Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.3.2.1 Asia Pacific Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.2.2 Asia Pacific In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.3 Asia Pacific Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
8.3.4 Japan Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.4.1 Japan Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.4.2 Japan Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.3.4.2.1 Japan Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.4.2.2 Japan In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.5 China Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.5.1 China Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.5.2 China Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.3.5.2.1 China Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.5.2.2 China In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.6 India Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.6.1 India Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.6.2 India Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.3.6.2.1 India Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.6.2.2 India In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.7 South Korea Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.7.1 South Korea Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.7.2 South Korea Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.3.7.2.1 South Korea Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.7.2.2 South Korea In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.8 Australia Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.8.1 Australia Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.3.8.2 Australia Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.3.8.2.1 Australia Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.3.8.2.2 Australia In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.4 Middle East & Africa Cancer Tissue Diagnostics Market Revenue And Forecasts To 2027
8.4.1 Middle East & Africa Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.4.2 Middle East & Africa Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.4.2.1 Middle East & Africa Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.4.2.2 Middle East & Africa In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.4.3 Middle East & Africa Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
8.4.4 UAE Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.4.4.1 UAE Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.4.4.2 UAE Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.4.4.2.1 UAE Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.4.4.2.2 UAE In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.4.4.3 Saudi Arabia Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.4.4.4 Saudi Arabia Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.4.4.5 Saudi Arabia Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.4.4.5.1 Saudi Arabia Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.4.4.5.2 Saudi Arabia In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.4.5 South Africa Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.4.5.1 South Africa Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.4.5.2 South Africa Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.4.5.2.1 South Africa Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.4.5.2.2 South Africa In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.5 South And Central America Cancer Tissue Diagnostics Market Revenue And Forecasts To 2027
8.5.1 South and Central America Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.5.2 South and Central America Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.5.2.1 South and Central America Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.5.2.2 South and Central America In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.5.3 South and Central America Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
8.5.4 Argentina Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.5.4.1 Argentina Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.5.4.2 Argentina Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.5.4.2.1 Argentina Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.5.4.2.2 Argentina In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.5.4.3 Brazil Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.5.4.4 Brazil Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
8.5.4.5 Brazil Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
8.5.4.5.1 Brazil Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8.5.4.5.2 Brazil In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
9. Cancer Tissue Diagnostics Market – Industry Landscape
9.1 Overview
9.2 Growth Strategies In The Cancer Tissue Diagnostics Market, 2016-2019
9.3 Organic Growth Strategies
9.3.1 Overview
9.4 Organic Growth Strategies in the Cancer Tissue Diagnostics Market, 2016-2019 (%)
9.4.1 Product Launches
9.4.1.1 Recent Product Launches By Players In The Cancer Tissue Diagnostics Market
9.4.2 Product Approvals
9.4.2.1 Recent Product Approvals By Players In The Cancer Tissue Diagnostics Market
9.4.3 Expansion & Other Activities
9.4.3.1 Recent Expansion & Other Activities By Players In The Cancer Tissue Diagnostics Market
9.4.4 Product Enhancements
9.4.4.1 Recent Product Enhancements By Players In The Cancer Tissue Diagnostics Market
9.5 Inorganic Growth Strategies
9.5.1 Overview
9.6 Inorganic Growth Strategies in the Cancer Tissue Diagnostics Market, 2016-2019 (%)
9.6.1 Agreements
9.6.1.1 Recent Agreements By Players In The Cancer Tissue Diagnostics Market
9.6.2 Partnerships & Collaborations
9.6.2.1 Recent Partnerships & Collaborations By Players In The Cancer Tissue Diagnostics Market
9.6.3 Acquisitions
9.6.3.1 Recent Acquisitions By Players In The Cancer Tissue Diagnostics Market
10. Cancer Tissue Diagnostics Market–Key Company Profiles
10.1 Bio-Rad Laboratories, Inc.
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Financial Information
10.1.4 Product Portfolio
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Thermo Fisher Scientific, Inc.
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Financial Information
10.2.4 Product Portfolio
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 F. Hoffmann-La Roche Ltd.
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Financial Overview
10.3.4 Product Portfolio
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Abbott
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Financial Overview
10.4.4 Product Portfolio
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Enzo Biochem Inc.
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Financial Overview
10.5.4 Product Portfolio
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Agilent Technologies, Inc.
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Financial Overview
10.6.4 Product Portfolio
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Cancer Genetics Inc.
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Financial Overview
10.7.4 Product Portfolio
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Merck Kgaa (Sigma-Aldrich)
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Financial Overview
10.8.4 Product Portfolio
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Abcam Plc.
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Financial Overview
10.9.4 Product Portfolio
10.9.5 SWOT Analysis
10.9.6 Key Developments
10.10 Danaher
10.10.1 Key Facts
10.10.2 Business Description
10.10.3 Financial Information
10.10.4 Product Portfolio
10.10.5 SWOT Analysis
10.10.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary Of Terms
LIST OF TABLES
Table 1. North America Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 2. North America Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 3. North America In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 4. US Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 5. US Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 6. US In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 7. Canada Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 8. Canada Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 9. Canada In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 10. Mexico Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 11. Mexico Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 12. Mexico In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 13. Europe Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 14. Europe Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 15. Europe In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 16. UK Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 17. UK Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 18. UK In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 19. Germany Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 20. Germany Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 21. Germany In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 22. France Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 23. France Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 24. France In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 25. Italy Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 26. Italy Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 27. Italy In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 28. Spain Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 29. Spain Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 30. Spain In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 31. Asia Pacific Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 32. Asia Pacific Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 33. Asia Pacific In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 34. Japan Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 35. Japan Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 36. Japan In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 37. China Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 38. China Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 39. China In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 40. India Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 41. India Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 42. India In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 43. South Korea Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 44. South Korea Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 45. South Korea In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 46. Australia Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 47. Australia Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 48. Australia In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 49. Middle East & Africa Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 50. Middle East & Africa Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 51. Middle East & Africa In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 52. UAE Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 53. UAE Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 54. UAE In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 55. Saudi Arabia Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 56. Saudi Arabia Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 57. Saudi Arabia In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 58. South Africa Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 59. South Africa Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 60. South Africa In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 61. South and Central America Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 62. South and Central America Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 63. South and Central America In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 64. Argentina Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 65. Argentina Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 66. Argentina In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 67. Brazil Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
Table 68. Brazil Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 69. Brazil In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
Table 70. Recent Product Launches in the Cancer Tissue Diagnostics Market
Table 71. Recent product Approvals in the Cancer Tissue Diagnostics Market
Table 72. Recent Expansion & Other Activities By Players In The Cancer Tissue Diagnostics Market
Table 73. Recent Product Enhancements By Players In The Cancer Tissue Diagnostics Market
Table 74. Recent Agreements By Players In The Cancer Tissue Diagnostics Market
Table 75. Recent Partnerships & Collaborations By Players In The Cancer Tissue Diagnostics Market
Table 76. Recent Acquisitions By Players In The Cancer Tissue Diagnostics Market
Table 77. Glossary of Terms, Cancer Tissue Diagnostics Market
LIST OF FIGURES
Figure 1. Cancer Tissue Diagnostics Market Segmentation
Figure 2. Cancer Tissue Diagnostics Segmentation, by Region
Figure 3. Asia Pacific Cancer Tissue Diagnostics Market, Revenue (US$ Mn), By Geography 2018 & 2027
Figure 4. Global Cancer Tissue Diagnostics Market By Test Type, Market Share (%), 2018
Figure 5. North America : PEST Analysis
Figure 6. Europe: PEST Analysis
Figure 7. Asia - Pacific: PEST Analysis
Figure 8. Middle East & Africa: PEST Analysis
Figure 9. South & Central America: PEST Analysis
Figure 10. Most Prevalent Forms of Cancers Globally, 2018
Figure 11. Cancer Tissue Diagnostics Market Impact Analysis of Driver and Restraints
Figure 12. Global Cancer Tissue Diagnostics Market – Revenue Forecasts and Analysis – 2018- 2027
Figure 13. Global Cancer Tissue Diagnostics Market – by Geography Forecasts and Analysis – 2018- 2027
Figure 14. Prominent Players in the Cancer Tissue Diagnostics Market
Figure 15. Global Cancer Tissue Diagnostics Market, by Test Type 2018 & 2027 (%)
Figure 16. Global Immunohistochemical Tests Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Global Breast Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Global Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Global Prostate Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Global Stomach Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Global Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Global In Situ Hybridization Tests Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Global Breast Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Global Lung Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Global Bladder Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Global Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 27. North America Cancer Tissue Diagnostics Market Revenue Overview, by Country, 2018 (US$ Mn)
Figure 28. North America Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. North America Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027, By Country (%)
Figure 30. US Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 31. Canada Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 32. Mexico Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 33. Europe Cancer Tissue Diagnostics Market Revenue Overview, by Country, 2018 (US$ MN)
Figure 34. Europe Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 35. Europe Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
Figure 36. UK Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 37. Germany Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 38. France Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 39. Italy Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 40. Spain Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 41. Asia Pacific Cancer Tissue Diagnostics Market Revenue Overview, by Country, 2018 (US$ MN)
Figure 42. Asia Pacific Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 43. Asia Pacific Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
Figure 44. Japan Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 45. China Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 46. India Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 47. South Korea Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 48. Australia Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 49. Middle East & Africa Cancer Tissue Diagnostics Market Revenue Overview, by Country, 2018 (US$ MN)
Figure 50. Middle East & Africa Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 51. Middle East & Africa Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
Figure 52. UAE Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 53. Saudi Arabia Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 54. South Africa Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 55. South and Central America Cancer Tissue Diagnostics Market Revenue Overview, by Country, 2018 (US$ MN)
Figure 56. South and Central America Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 57. South and Central America Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
Figure 58. Argentina Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 59. Brazil Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 60. Growth Strategies in the Cancer Tissue Diagnostics Market, 2016-2019
Figure 61. Organic Growth Strategies in the Cancer Tissue Diagnostics Market, 2016-2019 (%)
Figure 62. Inorganic Developments in the Cancer Tissue Diagnostics Market, 2016-2019(%)
The List of Companies
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- Abbott
- Enzo Life Sciences, Inc.
- Agilent Technologies, Inc.
- Cancer Genetics Inc.
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Abcam plc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For